Stratos Wealth Partners LTD. Sells 3,179 Shares of Novo Nordisk A/S (NYSE:NVO)

Stratos Wealth Partners LTD. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 11.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,361 shares of the company’s stock after selling 3,179 shares during the period. Stratos Wealth Partners LTD.’s holdings in Novo Nordisk A/S were worth $2,182,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth about $28,000. Capital Performance Advisors LLP purchased a new position in Novo Nordisk A/S in the third quarter worth about $42,000. Albion Financial Group UT lifted its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares in the last quarter. Sound Income Strategies LLC grew its holdings in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares during the last quarter. Finally, Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $48,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on NVO. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 0.9 %

Shares of NVO stock opened at $86.39 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market cap of $387.66 billion, a price-to-earnings ratio of 27.96, a PEG ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The firm has a fifty day moving average price of $91.86 and a 200-day moving average price of $111.83.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.16 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.